NCT02293915View on ClinicalTrials.gov

An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

818

Participants

Timeline

Start Date

April 1, 2014

Primary Completion Date

June 29, 2018

Study Completion Date

September 28, 2018

Conditions
Mild to Moderate Alzheimer DiseaseCognitive Impairment
Interventions
DRUG

Sodium oligo-mannurarate 900mg

sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks

DRUG

Placebo

simulant of sodium oligo-mannurarate capsule

Trial Locations (16)

100005

Beijing, Beijing

200030

Shanghai, Shanghai

250021

Jinan, Jinan

300052

Tianjin, Tianjin

310016

Hangzhou, Hangzhou

400010

Chongqing, Chongqing

430077

Wuhan, Wuhan

610041

Sichuan, Chengdu

Unknown

Fujian, Fuzhou

Guangzhou, Guangzhou

Changsha, Changsha

Nanjing, Nanjing

Suzhou, Suzhou

Yangzhou, Yangzhou

Xi'an, Xi’an

Wenzhou, Wenzhou

All Listed Sponsors
lead

Shanghai Greenvalley Pharmaceutical Co., Ltd.

INDUSTRY

NCT02293915 - An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease | Biotech Hunter | Biotech Hunter